Research and Markets: Global Life Sciences Trends and Opportunities 2012-2015: Pharma, Diagnostics, and Research Industry Converge to Address Complex Disease Challenge
DUBLIN--(BUSINESS WIRE)--Jan 9, 2013--Research and Markets ( http://www.researchandmarkets.com/research/7g432v/global_life ) has announced the addition of Frost & Sullivan's new report "Global Life Sciences Trends and Opportunities 2012-2015: Pharma, Diagnostics, and Research Industry Converge to Address Complex Disease Challenge" to their offering.
Frost & Sullivan's global life sciences team analyzes the impact of important changes and key trends across the total pharmaceutical/biotechnology, diagnostics, and life sciences research industries. This research deliverable captures the global life sciences trends and opportunities for the period of 2012-2015, as supported by Frost & Sullivan's proprietary research and leading industry experts. Topics include generics and biosimilars, emerging markets, pharmaceutical outsourcing, novel therapeutics, next generation diagnostics, research and development laboratories, and clinical laboratories.
Executive Summary This research deliverable summarizes the global life sciences trends and opportunities from 2012 to 2015 as supported by Frost & Sullivan proprietary research and leading industry experts.
Life Sciences Trends and Opportunities: Executive Summary, Global, 2012-2015 1 Frost & Sullivan has identified three growth strategies implemented by pharmaceutical companies in response to industry challenges: A focus on complex disease, open innovation programs, and emerging markets.
2 Pharmaceutical companies are leveraging specialized contract research organizations to enter emerging markets and biosimilar markets. Companion diagnostics co-developed for targeted therapies present opportunities for in vitro diagnostic companies to capture some of the pharmaceutical outsourcing market.
3 Disappearing government financing in research, laboratory workforce shortages, and a weakened economy contribute to the need for all laboratories to be more efficient. The effect of these restraining forces on the R&D and clinical laboratory industries is not expected to improve in the near-term.
4 Faster, more sensitive, and more cost-effective research tools enable shorter timelines between initial discovery and ending with novel tests and therapeutics that will impact modern healthcare. Frost & Sullivan identifies three technologies with this potential: next-generation sequencing, microRNA, and digital PCR.
5 Clinical genetic technologies have become integral to modern healthcare, and the molecular diagnostic, cancer diagnostics, and non-invasive prenatal testing segments provide clear indications for continuing double-digit revenue growth.
Key Topics Covered: 1 Executive Summary 2 Daunting Challenges for the Pharmaceutical Industry 3 Pharma's New Growth Strategies 4 Curbing the Costs of Drug Development 5 Lean LaboratoriesDoing More With Less 6 Novel Biomarker Discovery Leading to Novel Therapeutics 7 Genetic Technologies are Integral to Healthcare 8 Conclusions 9 Appendix 10 The Frost & Sullivan Story For more information visithttp://www.researchandmarkets.com/research/7g432v/global_life Source: Frost & SullivanCONTACT: Research and Markets Laura Wood, Senior Manager.
firstname.lastname@example.org U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector:Healthcare and Medical Devices,Pharmaceuticals KEYWORD: INDUSTRY KEYWORD: PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES SOURCE: Research and Markets Copyright Business Wire 2013 PUB: 01/09/2013 04:38 AM/DISC: 01/09/2013 04:38 AM http://www.businesswire.com/news/home/20130109005564/